Thai Public Health Minister Mongkol Songkhla plans to break patents on an antiretroviral drug and a drug for heart disease by issuing compulsory licenses to produce lower-cost versions,
Access Pharmaceuticals, Inc. announced today that it was issued U.S. Patent No. 7,166,733 by the U.S. Patent and Trademark Office. This patent, entitled "O,O'-Amidomalonato and N,O-Amidom
Archus Orthopedics, Inc. has announced that the European Patent Office has confirmed the validity of its patent number EP-B-1223872 following an Opposition that concluded with oral proceedings on Ja
Nventa Biopharmaceuticals has announced that the U.S. Patent and Trademark Office has issued Patent Number 7,157,089 to Nventa.The patent provides coverage for compositions of fusion protein
The Swiss pharmaceutical giant Novartis is in court in India this week challenging the country's patent laws.The drug company is attempting to overturn the Indian government's rejection of it
GlaxoSmithKline has issued an update on US patent litigation regarding Valtrex (valacyclovir), an antiviral drug used for the treatment and suppression of genital herpes, herpes zoster (shingles), and col
Odyssey Thera announced today that on January 9, 2007, the United States Patent and Trademark Office granted U.S. Patent No. 7,160,691. On January 23, 2007, the USPTO also granted U.S. Patent No.
Martinsried-based drug discovery and development company 4SC AG announced today that the US Patent and Trademark Office (ASPTO) has granted the patent with the US patent number 7,176,241 for its drug candi
Human DNA patents are unlikely to be the barrier to medical and scientific innovation that they were first feared to be, according to new findings published this week. In fact in recent years new guidelines at patent offices, legal developments
QLT Inc. announced that its wholly-owned subsidiary, QLT USA, Inc. (formerly Atrix Laboratories, Inc.) has reached an agreement to settle the litigation captioned "TAP Pharmaceutical Products Inc., Tak
GTI-2501 has shown a favourable safety profile in preclinical studies and in a Phase I clinical trial. The drug is currently in a Phase II clinical trial, in combination with docetaxel, for the treatment of hormone refractory prostate cancer. Initial testing of GT-2501 demonstrated strong antitumor activity in preclinical studies of prostate cancer and a variety of other human tumor types.
This European patent allowance follows a patent that was issued by the United States Patent Office in September 2000. A patent application for GTI-2501 has been filed in Canada and in numerous other international jurisdictions.
"Lorus Therapeutics is focused on developing anticancer drugs which complement the efficacy of more toxic chemotherapies without adding significant additional toxicity," said Dr. Jim Wright, CEO of Lorus Therapeutics. "We are pleased with the mild side effect profile previously observed with GTI-2501 alone, and the strong data and rationale supporting the ongoing clinical program in combination treatment for prostate cancer."
Dr. Wright added: "This European patent allowance contributes to our strong global intellectual property portfolio, which is an important strategy for enhancing shareholder value."
GTI-2501 is an antisense oligonucleotide complementary to the R1 component of ribonucleotide reductase, which component is essential for DNA replication and tumor cell proliferation. GTI-2501 is designed to exert its activity by specific downregulation of the R1 component of ribonucleotide reductase. In preclinical studies, GTI-2501 showed significant antitumor activity against prostate cancer and a variety of other tumor types including colon, pancreas, NSCLC, breast, ovary, melanoma, brain (glioblastoma-astrocytoma), renal, cervical, lymphoma and leukemia.
To date, GTI-2501 has concluded a Phase I clinical trial.
http://www.lorusthera.com/